I. Non-pharmacological measures. Salt restriction, potassium-rich diet, appropriate activity, and emotional relaxation are safe and effective treatments for combined hypertension in pregnancy and should be used as the basis for pharmacological treatment. Drug selection and application are limited by the lack of rigorous clinical validation of the safety of all antihypertensive drugs for the fetus and the teratogenic effects of some drugs found in animal experiments. Antihypertensive drugs during pregnancy should not be used too aggressively, and the main purpose of treatment is to ensure the safety of mother and child and the smooth progress of pregnancy. The strategy of treatment, duration of administration and choice of medication depend on the degree of elevated blood pressure and the assessment of the risks associated with elevated blood pressure. After receiving non-pharmacologic measures, pharmacologic therapy should be initiated when blood pressure is ≥150/100 mmhg, and the goal of treatment is to control blood pressure to 130–140/80–90 mmhg. II. Drug selection. Commonly used intravenous antihypertensive drugs include methyldopa, labetalol, and magnesium sulfate. ACEI (priligy) ARB (sartan) is prohibited during pregnancy. The choice of drugs: Class A, magnesium sulfate; Class B, methyldopa, hydrochlorothiazide; Class C, labetalol, metoprolol, nifedipine. Note: Grade A, not shown to be dangerous to the fetus in early pregnant women with controls and probably minimal harm to the fetus; Grade B, not shown to be dangerous to the fetus in animal reproduction tests but no controls in pregnant women or shown to be adverse in animal reproduction tests but no certainty of side effects in control groups of early pregnant women; Grade C, proven to be adverse to the fetus in studies in animals but in no control group in women or no available information in studies in women and animals, and the drug is given only when the balance of benefits to the fetus outweighs the harms.